Predicting chemotherapy-induced myelosuppression in colorectal cancer: An interpretable, machine learning-based nomogram

Table 1 Baseline characteristics of colorectal cancer patients, n (%)

Characteristic	Overall (n = 765)	Training set (n = 612)	Validation set (n = 153)	P value
Age, median (95%CI)	62.26 (61.58-62.96)	62.12 (61.36-62.88)	62.84 (61.16-64.51)	0.422
BSA, median (95%CI)	1.71 (1.69-1.72)	1.71 (1.69-1.72)	1.71 (1.68-1.74)	0.996
BMI, median (95%CI)	22.94 (22.70-23.17)	22.99 (22.72-23.26)	22.75 (22.23-23.27)	0.428
ALB, median (95%CI)	37.53 (37.27-37.80)	37.48 (37.19-37.50)	37.74 (37.10-38.37)	0.453
CEA, median (95%CI)	182.30 (125.72-246.75)	178.10 (115.79-240.41)	199.10 (53.75-344.45)	0.770
CA19-9, median (95%CI)	169.03 (113.66-237.21)	177.95 (108.12-247.78)	133.33 (0.11-266.55)	0.571
CA125, median (95%CI)	22.20 (19.20-25.77)	21.93 (18.30-25.56)	23.30 (13.48-33.12)	0.804
Gender				0.607
Male	449 (58.7)	362 (59.15)	87 (56.86)
Female	316 (41.3)	250 (40.85)	66 (43.14)
Smoking				0.572
Yes	275 (35.9)	223 (36.44)	52 (33.99)
No	316 (41.3)	389 (63.56)	101 (66.01)
Diabetes				0.529
Yes	128 (16.7)	105 (17.16)	23 (15.03)
No	637 (83.2)	507 (82.84)	130 (84.97)
Hypertension				0.417
Yes	307 (40.1)	250 (40.85)	57 (37.25)
No	458 (59.8)	362 (59.15)	96 (62.75)
T				0.491
1	18 (2.4)	15 (2.45)	3 (1.96)
2	84 (11.0)	67 (10.95)	17 (11.11)
3	264 (34.5)	323 (52.78)	76 (49.67)
4	399 (52.2)	207 (33.82)	57 (37.25)
N				0.255
0	4 (0.5)	126 (20.59)	36 (23.53)
1	162 (21.2)	261 (42.65)	68 (44.44)
2	270 (35.3)	222 (36.27)	48 (31.37)
3	329 (43.0)	3 (0.49)	1 (0.65)
M				0.103
0	355 (46.4)	293 (47.88)	62 (40.52)
1	410 (53.5)	319 (52.12)	91 (59.48)
Staging				0.180
I	15 (2.0)	11 (1.8)	4 (2.61)
II	66 (8.6)	56 (9.15)	10 (6.54)
III	267 (34.9)	219 (35.78)	48 (31.37)
IV	417 (54.5)	326 (53.27)	91 (59.48)
Position				0.687
Ascending colon	21 (2.7)	118 (19.28)	30 (19.61)
Transverse colon	27 (3.5)	15 (2.45)	6 (3.92)
Descending colon	148 (19.3)	24 (3.92)	3 (1.96)
Sigmoid colon	209 (27.3)	164 (26.8)	45 (29.41)
Rectum	360 (47.1)	291 (47.55)	69 (45.1)
Hepatic metastasis				0.195
Yes	261 (34.1)	202 (33.01)	59 (38.56)
No	504 (65.8)	410 (66.99)	94 (61.44)
Lung metastasis				0.064
Yes	214 (27.9)	162 (26.47)	52 (33.99)
No	551 (72.0)	450 (73.53)	101 (66.01)
Peritoneum metastasis				0.201
Yes	47 (6.1)	41 (6.7)	6 (3.92)
No	718 (93.8)	571 (93.3)	147 (96.08)
KRAS				0.961
Yes	124 (16.2)	99 (16.18)	25 (16.34)
No	641 (83.7)	513 (83.82)	128 (83.66)
BRAF				0.051
Yes	15 (1.9)	15 (2.45)	0 (0)
No	750 (98)	597 (97.55)	153 (100)
TP53				0.286
Yes	61 (7.9)	52 (8.5)	9 (5.88)
No	704 (92)	560 (91.5)	144 (94.12)
Myelosuppression				0.336
Yes	250 (32.6)	195 (31.86)	55 (35.95)
No	515 (67.3)	417 (68.14)	98 (64.05)
Chemotherapy cycles				0.572
1-2 cycles	315 (41.2)	258 (42.16)	57 (37.25)
3-4 cycles	237 (31.0)	182 (29.74)	55 (35.95)
5 or more cycles	213 (27.8)	172 (28.1)	41 (26.8)
Chemotherapy regimens				0.248
CapeOx	571 (74.6)	463 (75.65)	108 (70.59)
FOLFOX	85 (11.1)	63 (10.29)	22 (14.38)
FOLFIRI	109 (14.2)	86 (14.05)	23 (15.03)

BSA: Body surface area; BMI: Body mass index; ALB: Albumin; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; CI: Confidence interval; T: Tumor; N: Node; M: Metastasis.